BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

...FDA to work with in this area.”Under FDA Commissioner Scott Gottlieb, FDA devised a new paradigm...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...
BioCentury | Jan 13, 2021
Product Development

On the back of mRNA vaccine validation, Moderna adds three infectious disease programs to pipeline

On the back of its successful development of Moderna COVID-19 vaccine (mRNA-1273), Moderna has added three preclinical infectious disease vaccine programs to its pipeline, bringing its total number...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

...by integrating preprint servers into the publication paradigm...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...straightforward and simple. And it was a paradigm...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

...prior to the pandemic.“This is 100% a paradigm...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...a survival benefit in solid tumors, Berman said. “I can tell you, this is a pioneering paradigm...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...that “there’s a lot of complementarity here.”“We are bringing a lot of really great assets, paradigm-shifting...
...way that we can work together.” “We are bringing a lot of really great assets, paradigm-shifting...
Items per page:
1 - 10 of 723
BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

...FDA to work with in this area.”Under FDA Commissioner Scott Gottlieb, FDA devised a new paradigm...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...round to assess whether a well-traveled CETP inhibitor can find a place in the treatment paradigm...
BioCentury | Jan 13, 2021
Finance

IPO filing reveals details of Sana’s deep pipeline, aggregation of next-generation gene and cell therapy technologies

With its IPO filing Wednesday, well-funded start-up Sana has lifted the lid on a suite of technologies it has aggregated since 2018, giving it a pipeline of 11 cell and gene therapies. Its first INDs...
BioCentury | Jan 13, 2021
Product Development

On the back of mRNA vaccine validation, Moderna adds three infectious disease programs to pipeline

On the back of its successful development of Moderna COVID-19 vaccine (mRNA-1273), Moderna has added three preclinical infectious disease vaccine programs to its pipeline, bringing its total number...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

...by integrating preprint servers into the publication paradigm...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...straightforward and simple. And it was a paradigm...
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

...prior to the pandemic.“This is 100% a paradigm...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...a survival benefit in solid tumors, Berman said. “I can tell you, this is a pioneering paradigm...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...that “there’s a lot of complementarity here.”“We are bringing a lot of really great assets, paradigm-shifting...
...way that we can work together.” “We are bringing a lot of really great assets, paradigm-shifting...
Items per page:
1 - 10 of 723